NCT03285412 - CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

December 12, 2017

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions

Breast Cancer

Interventions

DRUG

Ribociclib

Ribociclib is a drug designed to block certain proteins called cyclin-dependent protein kinases 4 and 6 (CDK4/6). These proteins are needed for cells to divide and may also control the ability of certain cancers to grow.

OTHER

Endocrine therapy

Hormone therapy

Trial Locations (3)

02214

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

01923

Mass General/North Shore Cancer Center, Danvers